Alnylam Grants Integrated DNA Technologies License to Kreutzer-Limmer Patents for the RNA Interference Research Products Market
Alnylam Pharmaceuticals, Inc. and Integrated DNA Technologies, Inc. (IDT), supplier of custom nucleic acids in the U.S., announced that Alnylam has granted IDT a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
Alnylam's IP estate includes certain 'fundamental' patents and patent applications that claim the broad structural and functional properties of synthetic RNAi products. These include the Kreutzer-Limmer I and II patents, acquired through the Ribopharma merger: EP Patent No. 1144623, covering methods, medicaments and uses of siRNAs with up to 25 nucleotides complementary to a target gene; EP Patent No. 1214945, covering compositions, methods, and uses of siRNAs with a length between 15 and 49 nucleotides; and EP Patent No. 1352061, covering therapeutic compositions, methods, and uses of siRNA and derivatives directed toward over 125 disease targets.
Other news from the department business & finance
